Site-Specific PEGylated Interferon Dimer via Dock-and-Lock
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a general method of PEGylation that produces monoPEGylated or biPEGylated cytokine conjugates linked site-specifically to a predetermined location, retaining bioactivity and exhibiting improved in vivo efficacy, decreased toxicity, and superior pharmacokinetic properties.
Innovation Solution
The Dock-and-Lock (DNL) method is used to create PEGylated cytokines by attaching PEG residues to specific domains, forming stable and defined conjugates, with the option of forming disulfide bonds for stabilization, allowing for controlled clearance and enhanced therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If PEGylation is performed using conventional methods, then serum half-life is extended, but site-specificity and manufacturing precision deteriorate
Solution Approach 1:
The invention introduces a preliminary PEGylation step followed by dimerization. The monomeric units are PEGylated at specific cysteine residues before dimerization occurs, ensuring site-specific attachment. This preliminary action allows control over PEG placement while maintaining the ability to form defined dimeric structures, resolving the contradiction between extending serum half-life through PEGylation and maintaining manufacturing precision through site-specificity.
2Duration of action of stationary object
If PEG residues are attached to extend serum half-life, then clearance rate decreases, but bioactivity may be reduced
Solution Approach 1:
The invention attaches PEG residues specifically to cysteine residues located in regions that do not interfere with the cytokine's active sites. By selecting specific attachment locations (local quality), the PEG chains extend serum half-life through reduced renal clearance while maintaining the cytokine's bioactivity. The site-specific PEGylation ensures that critical functional regions remain accessible.
3Reliability
If dimeric structures are formed to enhance efficacy, then therapeutic effect is improved, but structural complexity increases
Solution Approach 1:
The invention constructs dimeric cytokines by joining two monomeric units through controlled dimerization of specific domains. This segmentation approach allows the formation of defined dimeric structures with enhanced therapeutic efficacy while maintaining manageable structural complexity. Each monomer can be independently characterized and the dimerization interface is well-defined, facilitating manufacturing and quality control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PEGylated cytokines demonstrate slower clearance and improved stability, maintaining bioactivity and efficacy, suitable for various therapeutic applications including cancer treatment and autoimmune diseases.
Implementation Method 1
The Dock-and-Lock (DNL) method is used to create PEGylated cytokines by attaching PEG residues to specific domains, forming stable and defined conjugates
Implementation Method 2
with the option of forming disulfide bonds for stabilization
Data Source
AI summary
The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a therapeutic agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two therapeutic agents and one PEG moiety. In alternative embodiments, the therapeutic agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one therapeutic agent. In more preferred embodiments, the therapeutic agent may comprise any peptide or protein of physiologic or therapeutic activity, preferably a cytokine, more preferably interferon-α2b. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases.